UNSPSC 51361809: Dexmedetomidine hydrochloride

This classification denotes an alpha-adrenergic agonist with the molecular formula C13H16N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1018WH7F9I, chemically known as 1h-imidazole, 4-(1-(2,3-dimethylphenyl)ethyl)-, monohydrochloride, (+-)- but more generally known as dexmedetomidine hydrochloride, which bears US NIH Compound Identifier 68601. European Medicines Agency schedules Dexmedetomidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20317.

UNSPSC 51361809 Dexmedetomidine hydrochloride is a Commodity code representing pharmaceutical products procured by state and local health agencies, though recent opportunities tagged under this code show a mix of pharmaceutical procurement activity that extends beyond dexmedetomidine specifically to broader naloxone, generic multi-source pharmaceuticals, and OTC products. State and local health authorities—county health departments, state health commissions, and cooperative purchasing alliances—use this code to solicit emergency medical supplies, generic pharmaceuticals, and community health products through competitive bidding and RFP processes. The work involves sourcing FDA-compliant pharmaceuticals with specified National Drug Codes, managing contracted delivery through authorized wholesalers, and maintaining compliance with the Drug Supply Chain Security Act and current Good Manufacturing Practices.

Recent activity centers in Florida and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (due July 26, 2023) seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the procurement included FEMA funding and required compliance with federal environmental regulations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products distributed across Minnesota, Oregon, and other participating jurisdictions, requiring vendors to work through three authorized wholesalers and meet fixed pricing, EDI capability, and price-competitiveness evaluation criteria weighted at 10, 5, and 75 percent respectively. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling early-stage procurement planning in that state.